Artelo Financial Statements From 2010 to 2026

ARTL Stock  USD 1.20  0.10  9.09%   
Artelo Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Artelo Biosciences' valuation are provided below:
Market Capitalization
3.5 M
Earnings Share
(19.50)
There are over one hundred nineteen available fundamental signals for Artelo Biosciences, which can be analyzed over time and compared to other ratios. We recommend to validate Artelo Biosciences' prevailing fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 4.8 M. The Enterprise Value is projected to slide to about 1.2 M
Check Artelo Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artelo Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 234.3 K, Selling General Administrative of 6.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Artelo financial statements analysis is a perfect complement when working with Artelo Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Artelo Stock
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Artelo Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.7 M2.8 MM
Slightly volatile
Cash570 K600 K1.6 M
Slightly volatile
Cash And Short Term Investments570 K600 K2.9 M
Slightly volatile
Common Stock Total Equity6.3 K4.5 K6.5 K
Pretty Stable
Common Stock Shares Outstanding734.1 KM515.3 K
Slightly volatile
Liabilities And Stockholders Equity2.7 M2.8 MM
Slightly volatile
Other Stockholder Equity65.1 M62 M20 M
Slightly volatile
Total Current Assets660.2 K695 KM
Slightly volatile
Common Stock1.9 KK6.9 K
Pretty Stable
Total Current Liabilities4.2 MM881.8 K
Slightly volatile
Accounts PayableM1.9 M570.2 K
Slightly volatile
Capital Surpluse12.4 M11.8 M5.3 M
Slightly volatile
Property Plant And Equipment Net46.1 K64 K22.7 K
Slightly volatile
Property Plant And Equipment Gross119.5 K113.8 K27.7 K
Slightly volatile
Capital Stock2.6 K2.7 K10.2 K
Slightly volatile
Short and Long Term Debt Total727.6 K693 K161.8 K
Slightly volatile

Artelo Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative6.3 MM2.2 M
Slightly volatile
Other Operating Expenses12.2 M11.6 M4.2 M
Slightly volatile
Total Operating Expenses12 M11.4 M4.2 M
Slightly volatile
Research Development3.2 M5.4 M2.5 M
Slightly volatile
Reconciled Depreciation441358329
Slightly volatile

Artelo Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow570 K600 K1.6 M
Slightly volatile
Begin Period Cash Flow3.2 M2.3 M2.1 M
Slightly volatile
Depreciation176.3 K167.9 K46.3 K
Slightly volatile
Stock Based Compensation985.7 K1.1 M533.8 K
Slightly volatile
Issuance Of Capital Stock95.8 K100.8 K1.9 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables472.2 K482.5 K436.7 K
Pretty Stable
Capex To Depreciation2.8 K2.6 K1.5 K
Slightly volatile
Cash Per Share0.550.583126.6158
Very volatile
Income Quality0.940.66150.8606
Very volatile
Intangibles To Total Assets0.760.7280.3374
Slightly volatile
Current Ratio0.160.17198.5315
Pretty Stable
Capex Per Share59.0956.2832.5621
Slightly volatile
Average Receivables8.5 K5.1 K7.8 K
Slightly volatile
Interest Debt Per Share0.910.8620.3033
Slightly volatile
Debt To Assets0.260.24740.0365
Slightly volatile
Ebt Per Ebit0.771.12930.9516
Pretty Stable
Quick Ratio0.160.17198.532
Pretty Stable
Cash Ratio0.140.14846.3559
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.021.381.245
Slightly volatile
Debt Ratio0.260.24740.0365
Slightly volatile

Artelo Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.8 M7.4 M5.7 M
Slightly volatile

Artelo Fundamental Market Drivers

Artelo Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Artelo Biosciences Financial Statements

Artelo Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Artelo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out the analysis of Artelo Biosciences Correlation against competitors.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Artelo Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(19.50)
Return On Assets
(1.36)
Return On Equity
(4.36)
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Artelo Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Artelo Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Artelo Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.